Growth hormone after oral glucose overload: Revision of reference values in normal subjects

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 7, 2008, Pages 1139-1144

  Rosário, Pedro W S ^a,c   Furtado, Mariana S ^b  

^a Santa Casa de Belo Horizonte e Setor de Hormônios do Laboratório ANALYS   (Brazil)

^b Faculdade de Medicina   (Brazil)

^c Laborato rio Analys Patologia   (Brazil)

Author keywords

Acromegaly; Growth hormone; Oral glucose tolerance test; Reference values

Indexed keywords

HUMAN GROWTH HORMONE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BODY MASS; BRAZIL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; MALE; MIDDLE AGED; REFERENCE VALUE; SECRETION;

ACROMEGALY; ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BRAZIL; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; YOUNG ADULT;

EID: 58149187468     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302008000700010     Document Type: Article

References (21)

1. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-9.
2. Trainer PJ. Editorial: acromegaly - consensus, what consensus? J Clin Endocrinol Metab. 2002;87:3534-6.
3. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355:2558-73.
4. Sheppard MC. GH and mortality in acromegaly. J Endocrinol Invest. 2005; 28(11 Suppl International):75-7.
5. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87:3537-42.
6. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary. 2003;6:175-80.
7. Freda PU, Landman RE, Sundeen RE, Post KD. Gender and age in the biochemical assessment of cure of acromegaly. Pituitary. 2001;4:163-71.
8. Endert E, van Rooden M, Fliers E, Prummel MF, Wiersinga WM. Establishment of reference values for endocrine testspart V: acromegaly. Neth J Med. 2006;64:230-5.
9. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab. 2004;89:658-61.
10. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism. 2003;52:181-5.
11. Markkanen H, Pekkarinen T, Välimäki MJ, Alfthan H, Kauppinen-Mäkelin R, Sane T, et al. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clin Chem. 2006;52:468-73.
12. Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A. Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol (Oxf). 2007;66:538-42.
13. Costa AC, Rossi A, Martinelli Jr CE, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab. 2002;87:3142-7.
14. Trainer PJ, Barth J, Sturgeon C, Wieringaon G. Consensus statement on the standardisation of GH assays. Eur J Endocrinol. 2006;155:1-2.
15. Arafat AM, Möhlig M, Weickert MO, Perschel FH, Purschwitz J, et al. Growth hormone response during OGTT: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls and the role of gender, age, and BMI. J Clin Endocrinol Metab. 2008;93:1254-62.
16. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab. 1994;78:1312-9.
17. Gullus, Keles H, Delibasi T, Tonyukuk V, Kamel N, Erdogan G. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol. 2004;150:465-71.
18. Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, et al. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf). 2006;64:245-9.
19. Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, et al. Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab. 2006;91:3891-6.
20. Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, et al. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf). 2006;65:250-6.
21. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89:495-500.